Epidemiological  ||| S:0 E:16 ||| JJ
survey  ||| S:16 E:23 ||| NN
of  ||| S:23 E:26 ||| IN
Trypanosoma  ||| S:26 E:38 ||| NNP
cruzi  ||| S:38 E:44 ||| JJ
infection  ||| S:44 E:54 ||| NN
in  ||| S:54 E:57 ||| IN
domestic  ||| S:57 E:66 ||| JJ
owned  ||| S:66 E:72 ||| JJ
cats  ||| S:72 E:77 ||| NNS
from  ||| S:77 E:82 ||| IN
the  ||| S:82 E:86 ||| DT
tropical  ||| S:86 E:95 ||| JJ
southeast  ||| S:95 E:105 ||| NN
of  ||| S:105 E:108 ||| IN
Mexico  ||| S:108 E:115 ||| NNP
American  ||| S:115 E:124 ||| NNP
trypanosomiasis  ||| S:124 E:140 ||| NN
is  ||| S:140 E:143 ||| VBZ
an  ||| S:143 E:146 ||| DT
infectious  ||| S:146 E:157 ||| JJ
disease  ||| S:157 E:165 ||| NN
of  ||| S:165 E:168 ||| IN
importance  ||| S:168 E:179 ||| NN
for  ||| S:179 E:183 ||| IN
public  ||| S:183 E:190 ||| JJ
health  ||| S:190 E:197 ||| NN
and  ||| S:197 E:201 ||| CC
caused  ||| S:201 E:208 ||| VBN
by  ||| S:208 E:211 ||| IN
the  ||| S:211 E:215 ||| DT
protozoa  ||| S:215 E:224 ||| JJ
Trypanosoma  ||| S:224 E:236 ||| NNP
cruzi  ||| S:236 E:242 ||| VBD
mainly  ||| S:242 E:249 ||| RB
transmitted  ||| S:249 E:261 ||| VBN
by  ||| S:261 E:264 ||| IN
triatomine  ||| S:264 E:275 ||| JJ
bugs ||| S:275 E:279 ||| NNS
.  ||| S:279 E:281 ||| .
The  ||| S:281 E:285 ||| DT
precise  ||| S:285 E:293 ||| JJ
role  ||| S:293 E:298 ||| NN
of  ||| S:298 E:301 ||| IN
cats  ||| S:301 E:306 ||| NNS
in  ||| S:306 E:309 ||| IN
the  ||| S:309 E:313 ||| DT
peridomestic  ||| S:313 E:326 ||| JJ
transmission  ||| S:326 E:339 ||| NN
of  ||| S:339 E:342 ||| IN
T.  ||| S:342 E:345 ||| NNP
cruzi  ||| S:345 E:351 ||| NN
and  ||| S:351 E:355 ||| CC
the  ||| S:355 E:359 ||| DT
mechanism  ||| S:359 E:369 ||| NN
by  ||| S:369 E:372 ||| IN
which  ||| S:372 E:378 ||| WDT
cats  ||| S:378 E:383 ||| VBZ
become  ||| S:383 E:390 ||| VBN
infected  ||| S:390 E:399 ||| NNS
remain  ||| S:399 E:406 ||| VBP
uncertain ||| S:406 E:415 ||| JJ
.  ||| S:415 E:417 ||| .
The  ||| S:417 E:421 ||| DT
objective  ||| S:421 E:431 ||| NN
of  ||| S:431 E:434 ||| IN
this  ||| S:434 E:439 ||| DT
work  ||| S:439 E:444 ||| NN
was  ||| S:444 E:448 ||| VBD
to  ||| S:448 E:451 ||| TO
determine  ||| S:451 E:461 ||| VB
the  ||| S:461 E:465 ||| DT
prevalence  ||| S:465 E:476 ||| NN
of  ||| S:476 E:479 ||| IN
T.  ||| S:479 E:482 ||| NNP
cruzi  ||| S:482 E:488 ||| JJ
infection  ||| S:488 E:498 ||| NN
in  ||| S:498 E:501 ||| IN
domestic  ||| S:501 E:510 ||| JJ
cats  ||| S:510 E:515 ||| NNS
from  ||| S:515 E:520 ||| IN
an  ||| S:520 E:523 ||| DT
urban  ||| S:523 E:529 ||| JJ
area  ||| S:529 E:534 ||| NN
of  ||| S:534 E:537 ||| IN
tropical  ||| S:537 E:546 ||| JJ
Mexico  ||| S:546 E:553 ||| NNP
by  ||| S:553 E:556 ||| IN
serological  ||| S:556 E:568 ||| NN
and  ||| S:568 E:572 ||| CC
molecular  ||| S:572 E:582 ||| JJ
methods  ||| S:582 E:590 ||| NNS
and  ||| S:590 E:594 ||| CC
evaluate  ||| S:594 E:603 ||| VB
associated  ||| S:603 E:614 ||| VBN
risk  ||| S:614 E:619 ||| NN
factors ||| S:619 E:626 ||| NNS
.  ||| S:626 E:628 ||| .
A  ||| S:628 E:630 ||| DT
total  ||| S:630 E:636 ||| NN
of  ||| S:636 E:639 ||| IN
220  ||| S:639 E:643 ||| CD
domestic  ||| S:643 E:652 ||| JJ
cats  ||| S:652 E:657 ||| NNS
from  ||| S:657 E:662 ||| IN
Merida  ||| S:662 E:669 ||| NNP
Yucatan ||| S:669 E:676 ||| NNP
,  ||| S:676 E:678 ||| ,
Mexico ||| S:678 E:684 ||| NNP
,  ||| S:684 E:686 ||| ,
were  ||| S:686 E:691 ||| VBD
studied ||| S:691 E:698 ||| VBN
.  ||| S:698 E:700 ||| .
Animals  ||| S:700 E:708 ||| NNS
older  ||| S:708 E:714 ||| JJR
than  ||| S:714 E:719 ||| IN
3  ||| S:719 E:721 ||| CD
months  ||| S:721 E:728 ||| NNS
were  ||| S:728 E:733 ||| VBD
blood  ||| S:733 E:739 ||| NN
sampled ||| S:739 E:746 ||| NN
.  ||| S:746 E:748 ||| .
Serum  ||| S:748 E:754 ||| NNP
and  ||| S:754 E:758 ||| CC
DNA  ||| S:758 E:762 ||| NNP
were  ||| S:762 E:767 ||| VBD
obtained ||| S:767 E:775 ||| VBN
.  ||| S:775 E:777 ||| .
Specific  ||| S:777 E:786 ||| JJ
T.  ||| S:786 E:789 ||| NNP
cruzi  ||| S:789 E:795 ||| VBD
IgG  ||| S:795 E:799 ||| JJ
antibodies  ||| S:799 E:810 ||| NNS
were  ||| S:810 E:815 ||| VBD
detected  ||| S:815 E:824 ||| VBN
using  ||| S:824 E:830 ||| VBG
a  ||| S:830 E:832 ||| DT
commercial  ||| S:832 E:843 ||| JJ
indirect  ||| S:843 E:852 ||| JJ
ELISA  ||| S:852 E:858 ||| NN
with  ||| S:858 E:863 ||| IN
an  ||| S:863 E:866 ||| DT
anti-cat  ||| S:866 E:875 ||| JJ
antibody  ||| S:875 E:884 ||| NN
HRP  ||| S:884 E:888 ||| NNP
labelled ||| S:888 E:896 ||| NN
.  ||| S:896 E:898 ||| .
Positive  ||| S:898 E:907 ||| JJ
cases  ||| S:907 E:913 ||| NNS
were  ||| S:913 E:918 ||| VBD
confirmed  ||| S:918 E:928 ||| VBN
by  ||| S:928 E:931 ||| IN
Western  ||| S:931 E:939 ||| JJ
blot  ||| S:939 E:944 ||| NNS
( ||| S:944 E:945 ||| -LRB-
WB ||| S:945 E:947 ||| NNP
) ||| S:947 E:948 ||| -RRB-
.  ||| S:948 E:950 ||| .
Polymerase  ||| S:950 E:961 ||| JJ
chain  ||| S:961 E:967 ||| NN
reaction  ||| S:967 E:976 ||| NN
( ||| S:976 E:977 ||| -LRB-
PCR ||| S:977 E:980 ||| NNP
)  ||| S:980 E:982 ||| -RRB-
was  ||| S:982 E:986 ||| VBD
also  ||| S:986 E:991 ||| RB
performed  ||| S:991 E:1001 ||| VBN
using  ||| S:1001 E:1007 ||| VBG
the  ||| S:1007 E:1011 ||| DT
primers  ||| S:1011 E:1019 ||| JJ
TC1  ||| S:1019 E:1023 ||| NN
and  ||| S:1023 E:1027 ||| CC
TC2 ||| S:1027 E:1030 ||| NNP
.  ||| S:1030 E:1032 ||| .
From  ||| S:1032 E:1037 ||| IN
the  ||| S:1037 E:1041 ||| DT
220  ||| S:1041 E:1045 ||| CD
cats ||| S:1045 E:1049 ||| NNS
,  ||| S:1049 E:1051 ||| ,
8.6 ||| S:1051 E:1054 ||| CD
%  ||| S:1054 E:1056 ||| NN
had  ||| S:1056 E:1060 ||| VBD
antibodies  ||| S:1060 E:1071 ||| NNS
against  ||| S:1071 E:1079 ||| IN
T.  ||| S:1079 E:1082 ||| NNP
cruzi  ||| S:1082 E:1088 ||| VBZ
using  ||| S:1088 E:1094 ||| VBG
ELISA  ||| S:1094 E:1100 ||| NNP
test  ||| S:1100 E:1105 ||| NN
and  ||| S:1105 E:1109 ||| CC
later  ||| S:1109 E:1115 ||| RB
confirmed  ||| S:1115 E:1125 ||| VBN
by  ||| S:1125 E:1128 ||| IN
WB ||| S:1128 E:1130 ||| NNP
.  ||| S:1130 E:1132 ||| .
In  ||| S:1132 E:1135 ||| IN
75  ||| S:1135 E:1138 ||| CD
cats  ||| S:1138 E:1143 ||| NNS
( ||| S:1143 E:1144 ||| -LRB-
34 ||| S:1144 E:1146 ||| CD
% ||| S:1146 E:1147 ||| NN
) ||| S:1147 E:1148 ||| -RRB-
,  ||| S:1148 E:1150 ||| ,
the  ||| S:1150 E:1154 ||| DT
sequence  ||| S:1154 E:1163 ||| NN
of  ||| S:1163 E:1166 ||| IN
ADNk  ||| S:1166 E:1171 ||| JJ
of  ||| S:1171 E:1174 ||| IN
T.  ||| S:1174 E:1177 ||| NNP
cruzi  ||| S:1177 E:1183 ||| NN
was  ||| S:1183 E:1187 ||| VBD
amplified ||| S:1187 E:1196 ||| VBN
.  ||| S:1196 E:1198 ||| .
The  ||| S:1198 E:1202 ||| DT
bad-regular  ||| S:1202 E:1214 ||| JJ
body  ||| S:1214 E:1219 ||| NN
condition  ||| S:1219 E:1229 ||| NN
was  ||| S:1229 E:1233 ||| VBD
the  ||| S:1233 E:1237 ||| DT
only  ||| S:1237 E:1242 ||| JJ
risk  ||| S:1242 E:1247 ||| NN
factor  ||| S:1247 E:1254 ||| NN
associated  ||| S:1254 E:1265 ||| VBN
with  ||| S:1265 E:1270 ||| IN
PCR  ||| S:1270 E:1274 ||| NNP
positive  ||| S:1274 E:1283 ||| JJ
to  ||| S:1283 E:1286 ||| TO
T.cruzi  ||| S:1286 E:1294 ||| CD
( ||| S:1294 E:1295 ||| -LRB-
P  ||| S:1295 E:1297 ||| NNP
< ||| S:1297 E:1299 ||| SYM
0.001 ||| S:1299 E:1304 ||| NNP
) ||| S:1304 E:1305 ||| -RRB-
.  ||| S:1305 E:1307 ||| .
In  ||| S:1307 E:1310 ||| IN
Mexico ||| S:1310 E:1316 ||| NNP
,  ||| S:1316 E:1318 ||| ,
there  ||| S:1318 E:1324 ||| EX
are  ||| S:1324 E:1328 ||| VBP
no  ||| S:1328 E:1331 ||| DT
previous  ||| S:1331 E:1340 ||| JJ
epidemiological  ||| S:1340 E:1356 ||| JJ
reports  ||| S:1356 E:1364 ||| NNS
that  ||| S:1364 E:1369 ||| WDT
demonstrate  ||| S:1369 E:1381 ||| VBP
the  ||| S:1381 E:1385 ||| DT
importance  ||| S:1385 E:1396 ||| NN
of  ||| S:1396 E:1399 ||| IN
the  ||| S:1399 E:1403 ||| DT
cat  ||| S:1403 E:1407 ||| NN
as  ||| S:1407 E:1410 ||| IN
a  ||| S:1410 E:1412 ||| DT
reservoir  ||| S:1412 E:1422 ||| NN
of  ||| S:1422 E:1425 ||| IN
T.  ||| S:1425 E:1428 ||| NNP
cruzi ||| S:1428 E:1433 ||| NN
.  ||| S:1433 E:1435 ||| .
Few  ||| S:1435 E:1439 ||| JJ
individuals  ||| S:1439 E:1451 ||| NNS
were  ||| S:1451 E:1456 ||| VBD
identified  ||| S:1456 E:1467 ||| VBN
with  ||| S:1467 E:1472 ||| IN
a  ||| S:1472 E:1474 ||| DT
serological  ||| S:1474 E:1486 ||| JJ
response  ||| S:1486 E:1495 ||| NN
because  ||| S:1495 E:1503 ||| IN
they  ||| S:1503 E:1508 ||| PRP
were  ||| S:1508 E:1513 ||| VBD
probably  ||| S:1513 E:1522 ||| RB
at  ||| S:1522 E:1525 ||| IN
an  ||| S:1525 E:1528 ||| DT
early  ||| S:1528 E:1534 ||| JJ
stage  ||| S:1534 E:1540 ||| NN
of  ||| S:1540 E:1543 ||| IN
infection  ||| S:1543 E:1553 ||| NN
or  ||| S:1553 E:1556 ||| CC
antibodies  ||| S:1556 E:1567 ||| NNS
were  ||| S:1567 E:1572 ||| VBD
not  ||| S:1572 E:1576 ||| RB
detected  ||| S:1576 E:1585 ||| VBN
because  ||| S:1585 E:1593 ||| IN
they  ||| S:1593 E:1598 ||| PRP
could  ||| S:1598 E:1604 ||| MD
be  ||| S:1604 E:1607 ||| VB
immunocompromised  ||| S:1607 E:1625 ||| NNS
( ||| S:1625 E:1626 ||| -LRB-
FIV ||| S:1626 E:1629 ||| NNP
,  ||| S:1629 E:1631 ||| ,
FeLV  ||| S:1631 E:1636 ||| JJ
or  ||| S:1636 E:1639 ||| CC
others ||| S:1639 E:1645 ||| NNS
) ||| S:1645 E:1646 ||| -RRB-
.  ||| S:1646 E:1648 ||| .
It  ||| S:1648 E:1651 ||| PRP
is  ||| S:1651 E:1654 ||| VBZ
necessary  ||| S:1654 E:1664 ||| JJ
to  ||| S:1664 E:1667 ||| TO
monitor  ||| S:1667 E:1675 ||| VB
PCR-positive  ||| S:1675 E:1688 ||| JJ
patients  ||| S:1688 E:1697 ||| NNS
and  ||| S:1697 E:1701 ||| CC
conduct  ||| S:1701 E:1709 ||| VB
further  ||| S:1709 E:1717 ||| JJ
studies  ||| S:1717 E:1725 ||| NNS
for  ||| S:1725 E:1729 ||| IN
better  ||| S:1729 E:1736 ||| JJR
understanding  ||| S:1736 E:1750 ||| NN
of  ||| S:1750 E:1753 ||| IN
the  ||| S:1753 E:1757 ||| DT
epidemiology  ||| S:1757 E:1770 ||| NN
and  ||| S:1770 E:1774 ||| CC
pathogenesis  ||| S:1774 E:1787 ||| NN
of  ||| S:1787 E:1790 ||| IN
Chagas  ||| S:1790 E:1797 ||| NNP
disease  ||| S:1797 E:1805 ||| NN
in  ||| S:1805 E:1808 ||| IN
domestic  ||| S:1808 E:1817 ||| JJ
cats ||| S:1817 E:1821 ||| NNS
.  ||| S:1821 E:1823 ||| .
